Natural Product (NP) Details
| General Information of the NP (ID: NP3875) | |||||
|---|---|---|---|---|---|
| Name |
Cryptoxanthin
|
||||
| Synonyms |
beta-Cryptoxanthin; Cryptoxanthin; 472-70-8; (3R)-beta,beta-caroten-3-ol; UNII-6ZIB13GI33; 6ZIB13GI33; (1R)-3,5,5-trimethyl-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-ol; Cryptoxanthins; beta,beta-carotene-3-ol; Neo-beta-cryptoxanthin; 3-Hydroxy-beta-carotene; beta-cryptoxanthins; beta,beta-Caroten-3-ol, (3R)-; SCHEMBL24469; CHEBI:10362; DTXSID30912309; ZINC4097702; beta-Cryptoxanthin, >=97% (TLC); LMPR01070269; HY-108059; CS-0027251; C08591; Q392062; 5-AMINOMETHYL-2-HYDROXY-BENZOICACIDMETHYLESTER; UNII-177RP9H0XI component DMASLKHVQRHNES-FKKUPVFPSA-N
Click to Show/Hide
|
||||
| Species Origin | Capsicum annum ... | Click to Show/Hide | |||
| Capsicum annum | |||||
| Disease | Stomach cancer [ICD-11: 2B72] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C40H56O
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CC(CC2(C)C)O)C)C)C
|
||||
| InChI |
1S/C40H56O/c1-30(18-13-20-32(3)23-25-37-34(5)22-15-27-39(37,7)8)16-11-12-17-31(2)19-14-21-33(4)24-26-38-35(6)28-36(41)29-40(38,9)10/h11-14,16-21,23-26,36,41H,15,22,27-29H2,1-10H3/b12-11+,18-13+,19-14+,25-23+,26-24+,30-16+,31-17+,32-20+,33-21+/t36-/m1/s1
|
||||
| InChIKey |
DMASLKHVQRHNES-FKKUPVFPSA-N
|
||||
| CAS Number |
CAS 472-70-8
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | BGC-823 | CVCL_3360 | Gastric cancer | Homo sapiens | ||
| Experimental
Result(s) |
The combination of crocin with cisplatin suppresses growth of gastric carcinoma cell line BGC-823 and promotes cell apoptosis. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | ATP-binding cassette A1 (ABCA1) | Molecule Info | [3] | |
| KEGG Pathway | ABC transporters | Click to Show/Hide | ||
| 2 | Fat digestion and absorption | |||
| NetPath Pathway | Leptin Signaling Pathway | Click to Show/Hide | ||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | Click to Show/Hide | ||
| Reactome | HDL-mediated lipid transport | Click to Show/Hide | ||
| 2 | PPARA activates gene expression | |||
| WikiPathways | Statin Pathway | Click to Show/Hide | ||
| 2 | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| 3 | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
| 4 | Lipid digestion, mobilization, and transport | |||
| 5 | SREBF and miR33 in cholesterol and lipid homeostasis | |||
| 6 | Folate Metabolism | |||
| 7 | Vitamin B12 Metabolism | |||
| 8 | Selenium Micronutrient Network | |||
